Compare UBER & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UBER | BSX |
|---|---|---|
| Founded | 2009 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4B | 137.8B |
| IPO Year | 2019 | 1992 |
| Metric | UBER | BSX |
|---|---|---|
| Price | $69.54 | $74.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 34 | 20 |
| Target Price | $106.70 | ★ $109.30 |
| AVG Volume (30 Days) | ★ 24.6M | 20.7M |
| Earning Date | 02-04-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.72 | ★ 55.20 |
| EPS | ★ 4.73 | 1.94 |
| Revenue | ★ $52,017,000,000.00 | $20,074,000,000.00 |
| Revenue This Year | $18.17 | $12.53 |
| Revenue Next Year | $14.66 | $10.88 |
| P/E Ratio | ★ $14.81 | $38.52 |
| Revenue Growth | 18.28 | ★ 19.87 |
| 52 Week Low | $60.63 | $72.69 |
| 52 Week High | $101.99 | $109.50 |
| Indicator | UBER | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 26.21 | 30.81 |
| Support Level | $69.45 | $72.69 |
| Resistance Level | $75.05 | $79.17 |
| Average True Range (ATR) | 2.70 | 2.52 |
| MACD | -0.76 | -1.26 |
| Stochastic Oscillator | 14.07 | 16.10 |
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 202 million users who order rides or food at least once a month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.